We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Roche consolidates grip on anti-angiogenesis market.
- Authors
Moran, Nuala
- Abstract
The article discusses ways in which the pharmaceutical company Roche is intending to consolidate its presence in the anti-angiogenesis market. The company recently signed a deal with the European companies ThromboGenics and BioInvent for a humanized monoclonal antibody (mAb) that binds placental growth factor (PIGF) in an attempt to understand tumor vasculature. Roche is also attempting to buy the remaining portion of the biotechnology company Genentech that it does not already own. This would be an effort to consolidate the franchise of the mAb Avastin. These efforts are further examined, and a chart is presented.
- Subjects
F. Hoffmann-La Roche Ltd.; NEOVASCULARIZATION inhibitors; THROMBOGENICS NV; BIOINVENT International AB; THERAPEUTIC use of monoclonal antibodies; BIOTECHNOLOGY industries; GENENTECH Inc.; MERGERS &; acquisitions; THERAPEUTICS
- Publication
Nature Biotechnology, 2008, Vol 26, Issue 10, p1055
- ISSN
1087-0156
- Publication type
Article
- DOI
10.1038/nbt1008-1055